{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:06:52Z","timestamp":1768518412228,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the potential association between tumor lysis syndrome (TLS) and drugs for the treatment of malignant melanoma (MM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Reports of TLS recorded in the FDA Adverse Event Reporting System (FAERS) (January 2004\u20132023q3) were identified. Demographic and clinical characteristics were described, and disproportionality signals were assessed through the Reporting Odds Ratio (ROR) and Information Component (IC). The latency of TLS with anticancer drugs was described based on parametric models. Subgroup analysis was conducted to explore the differences of TLS signals in different age and sex.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found 5 (1.49%), 59 (17.61%), 79 (23.58%), 19 (5.67%), 13 (3.88%), 13 (3.88%), 33 (9.85%), 49 (14.63%), 16 (4.78%) TLS reports with pembrolizumab, nivolumab, ipilimumab, dabrafenib, vemurafenib, dacarbazine, \u201cencorafenib and binimetinib\u201d, \u201cnivolumab and ipilimumab\u201d, \u201cdabrafenib and trametinib\u201d, respectively. The combination of encorafenib and binimetinib showed the strongest signal of TLS (IC<jats:sub>025<\/jats:sub> = 3.98). The median days of latency of TLS with combination of encorafenib and binimetinib is 2\u00a0days, which was much shorter than nivolumab (22.0\u00a0days) and ipilimumab (21.5\u00a0days). TLS cases associated with drugs for MM were predominantly recorded in females and aged 25\u201365\u00a0years. After excluding confounding factors such as pre-existing diseases and co-treated drugs, the disproportionate signal of TLS with \u201cencorafenib and binimetinib\u201d remained strong.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Stronger disproportionate signal of TLS was detected in MM patients using the combination of encorafenib and binimetinib than other drugs. Further research is needed to investigate the underlying mechanisms and identify patient-related predisposing factors to support safe prescribing of the combination of encorafenib and binimetinib.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1413154","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T07:30:32Z","timestamp":1725867032000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Shuang","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Wen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-Xin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur","family":"Sarangdhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ajg.2016.238","article-title":"Swallowed fluticasone propionate is an effective long-term maintenance therapy for children with eosinophilic esophagitis","volume":"111","author":"Andreae","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1053\/j.ackd.2021.09.007","article-title":"Tumor lysis syndrome","volume":"28","author":"Barbar","year":"2021","journal-title":"Adv. Chronic Kidney Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/leu.2011.109","article-title":"Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol","volume":"25","author":"Blum","year":"2011","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/CMR.0000000000000696","article-title":"Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass","volume":"30","author":"Byron","year":"2020","journal-title":"Melanoma Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/bjh.16278","article-title":"Emergencies in haematology: tumour lysis syndrome","volume":"188","author":"Durani","year":"2020","journal-title":"Br. J. Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"B8","first-page":"591","article-title":"Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030","volume":"64","author":"Guy","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","article-title":"Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review","volume":"95","author":"Howard","year":"2016","journal-title":"Ann. Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","article-title":"Treatment of advanced melanoma in 2020 and beyond","volume":"141","author":"Jenkins","year":"2021","journal-title":"J. Invest Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1158\/1078-0432.CCR-12-1092","article-title":"A pharmacokinetic\/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol","volume":"19","author":"Ji","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e18108","DOI":"10.7759\/cureus.18108","article-title":"Association of tumor lysis syndrome and metastatic melanoma","volume":"13","author":"Kelkar","year":"2021","journal-title":"Cureus"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.3390\/cancers14194652","article-title":"Melanoma management: from epidemiology to treatment and latest advances","volume":"14","author":"Lopes","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/11532850-000000000-00000","article-title":"Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluation","volume":"33","author":"Maignen","year":"2010","journal-title":"Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1756-8722-5-75","article-title":"Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies","volume":"5","author":"McBride","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/pds.1058","article-title":"The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions","volume":"14","author":"Moore","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12325-018-0665-5","article-title":"Causality assessment of olfactory and gustatory dysfunction associated with intranasal fluticasone propionate: application of the Bradford Hill criteria","volume":"35","author":"Muganurmath","year":"2018","journal-title":"Adv. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","article-title":"Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events","volume":"1","author":"Nakamura","year":"2015","journal-title":"J. Pharm. Health Care Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40264-024-01404-w","article-title":"Detection algorithms for simple two-group comparisons using spontaneous reporting systems","volume":"47","author":"Noguchi","year":"2024","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40264-020-00957-w","article-title":"Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase","volume":"43","author":"Sandberg","year":"2020","journal-title":"Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nbt.3623","article-title":"Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data","volume":"34","author":"Sarangdhar","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/cts.12899","article-title":"Therapeutic opportunities for intestinal angioectasia- targeting PPAR\u03b3 and oxidative stress","volume":"14","author":"Sarangdhar","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.6004\/jnccn.2021.0018","article-title":"NCCN Guidelines\u00ae insights: melanoma: cutaneous, version 2.2021","volume":"19","author":"Swetter","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1111\/1346-8138.15894","article-title":"Tumor lysis syndrome induced by BRAF\/MEK double blockade in a patient with metastatic melanoma: a first case report","volume":"48","author":"Tachibana","year":"2021","journal-title":"J. Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"679207","DOI":"10.3389\/fphar.2021.679207","article-title":"Immune checkpoint inhibitor-associated tumor lysis syndrome: a real-world pharmacovigilance study","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.5858\/arpa.2017-0278-RS","article-title":"Tumor lysis syndrome","volume":"143","author":"Williams","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40261-023-01308-0","article-title":"Tumor lysis syndrome with CD20 monoclonal antibodies for chronic lymphocytic leukemia: signals from the FDA adverse event reporting system","volume":"43","author":"Xia","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"B30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40264-016-0503-0","article-title":"Signal detection based on time to onset algorithm in spontaneous reporting system of China","volume":"40","author":"Zhang","year":"2017","journal-title":"Drug Saf."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1413154\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T07:30:37Z","timestamp":1725867037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1413154\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":30,"alternative-id":["10.3389\/fphar.2024.1413154"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1413154","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"article-number":"1413154"}}